Alkermes (ALKS) Cash & Equivalents Growth (3y) (2013 - 2026)
Alkermes (ALKS) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 29.96% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 20.41% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -2.73% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.02% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 3.22% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 52.71% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 36.93% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 10.41% |
| 10 | Alkermes | 8.78 Bn | 8.26 Bn | 331.33 Mn | 3.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.03% |
| Dec 31, 2025 | 9.93% |
| Sep 30, 2025 | 32.67% |
| Jun 30, 2025 | 26.97% |
| Mar 31, 2025 | 12.27% |
| Dec 31, 2024 | -4.81% |
| Sep 30, 2024 | 8.48% |
| Jun 30, 2024 | 27.48% |
| Mar 31, 2024 | 27.08% |
| Dec 31, 2023 | 18.78% |
| Sep 30, 2023 | 39.06% |
| Jun 30, 2023 | 52.16% |
| Mar 31, 2023 | 22.21% |
| Dec 31, 2022 | 12.80% |
| Sep 30, 2022 | 0.32% |
| Jun 30, 2022 | 9.13% |
| Mar 31, 2022 | 7.85% |
| Dec 31, 2021 | 8.16% |
| Sep 30, 2021 | 12.85% |
| Jun 30, 2021 | 18.35% |